Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia Sells 1,775 Shares

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 1,775 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $38.05, for a total value of $67,538.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Sandip Kapadia also recently made the following trade(s):

• On Tuesday, January 21st, Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00.

Harmony Biosciences Stock Up 1.9 %

NASDAQ HRMY opened at $39.54 on Friday. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 52 week low of $28.14 and a 52 week high of $41.61. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 0.51 and a beta of 0.78. The company has a fifty day moving average of $35.20 and a two-hundred day moving average of $35.22.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm’s revenue for the quarter was up 16.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.63 EPS. On average, analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after acquiring an additional 436 shares during the period. Mendota Financial Group LLC lifted its position in shares of Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after purchasing an additional 965 shares during the last quarter. CWM LLC lifted its position in shares of Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after purchasing an additional 775 shares during the last quarter. Quarry LP bought a new position in shares of Harmony Biosciences in the second quarter worth about $62,000. Finally, KBC Group NV increased its stake in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares during the period. Institutional investors own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HRMY. Raymond James reaffirmed an “outperform” rating and set a $40.00 target price on shares of Harmony Biosciences in a research note on Thursday, October 10th. Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. HC Wainwright reissued a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a research note on Monday. Mizuho lifted their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald increased their target price on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Harmony Biosciences has a consensus rating of “Buy” and a consensus price target of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.